Hepatitis C virus: Promising discoveries and new treatments

Table 2 Treatments for hepatitis C virus infection

Ref.	Treatment, wk	Genotype	SVR (total, cirrhotic, non-cirrhotic)	Previously treated
				Patients included
Davis et al[53]	IFN, 24	1	3; NA; NA	Yes
	IFN + RBV, 24		30; NA; NA
IDEAL Study Team[54]	PEG-IFN/RBV, 48	1	39.8-40.9; 42.1-43.6; 20.7-23.6	No
ADVANCE Study Team[48]	TVR + PEG-IFN/RBV	1	75; 62-81; 62	No
REALIZE Study Team[49]	TVR + PEG-IFN/RBV, 48	1	63-64; 28-84; NA	Yes
SPRINT-2 Investigators[47]	BOC + PEG-IFN/RBV, 28	1	67; 70; 50	No
	BOC + PEG-IFN/RBV, 48		68; 70; 50
RESPOND-2 Investigators[46]	BOC + PEG-IFN/RBV, 36	1	59; 35; 64	Yes
	BOC + PEG-IFN/RBV, 48		66; 77; 66
PILLAR[55]	SMP + PEG-IFN/RBV, 12	1	80.5; NA; 80.5	No
	SMP + PEG-IFN/RBV, 24		86.1; NA; 86.1
Gane et al[56]	SOF + RBV, 12	2 or 3	100; NA; 100	No
	SOF + PEG-IFN/RBV, 8		100; NA; 100
COSMOS[57]	SMP + SOF + RBV, 24	1	NA; 93;79	Yes
	SMP + SOF, 24		NA; 93; 100
	SMP + SOF + RBV, 12		NA; 93; 93
	SMP + SOF, 12		NA; 90; 94
OPTIMIST-1[58]	SMP + SOF, 8	1	83; NA; 83	Yes
	SMP + SOF, 12		97; NA; 97
OPTIMIST-2[59]	SMP + SOF, 12	1	83; 83; NA	Yes
AI444040 Study group[60]	DCV + SOF, 24	2 or 3	100; NA; NA	No
	DCV + SOF + RBV, 24		86; NA; NA	No
	DCV + SOF, 24	1	100; NA; NA	Yes
	DCV + SOF + RBV, 24		95-100; NA; NA
ALLY-3 Study Team[61]	DCV + SOF, 12	3	86-91; 63; 96	Yes
ION-2 Investigators[62]	LDV + SOF, 12	1	94; 86; 97	Yes
	LDV + SOF, 24		99; 100; 99
	LDV + SOF + RBV, 12		96; 87; 100
	LDV + SOF + RBV, 24		99; 100; 99
ION-3 Investigators[63]	LDV + SOF, 8	1	94; NA; 94	No
	LDV + SOF + RBV, 8		93; NA; 93
	LDV + SOF, 12		95; NA; 95
MALACHITE-I/II[64]	OBV + PTV/r + DSV + RBV, 12	1	97-99; NA; 97-99	Yes
PEARL-I[65]	OBV + PTV/r	4	91; NA; 91	No
	OBV + PTV/r + RBV		100; NA; 100	Yes
SAPPHIRE-II[66]	ABT-450/r + OBV + DSV + RBV, 12	1	96.3; NA; 93.6	Yes
TURQUOISE-II[67]	ABT-450/r + OBV + DSV + RBV, 12	1	91.8; 91.8; NA	Yes
	ABT-450/r + OBV + DSV + RBV, 24		95.9; 95.9; NA
ASTRAL-2 and ASTRAL-3[68]	SOF + VEL, 12	2	99; 100; 99	Yes
		3	95; 93; 98
C-WORTHY[69]	GZR + EBR, 12	1	91-97; 91-97; NA	Yes
	GZR + EBR + RBV, 12		90-94; 90-94; NA
	GZR + EBR, 18		94-97; NA; NA
	GZR + EBR + RBV, 18		97-100; NA; NA
Everson et al[70]	DCV + ASV + BCV, 12	1	88.8-89.5; 71.4-100; 87.5-91.1	No
	DCV + ASV + BCV + RBV, 12		85.7; 100; 85
SOUND-2[71]	FDV + deleobuvir + RBV, 16	1	59; NA; NA	No
	FDV + deleobuvir + RBV, 28		59-69; NA; NA
	FDV + deleobuvir + RBV, 40		52; NA; NA
	FDV + deleobuvir, 28		39; NA; NA

SVR: Sustained virological response; IFN: Interferon alfa; RBV: Ribavirin; PEG-IFN: Peginterferon alfa; TPV: Telaprevir; BOC: Boceprevir; SMP: Simeprevir; SOF: Sofosbuvir; DCV: Daclatasvir; LDV: Ledipasvir; OBV: Ombitasvir; PTV/r: Paritaprevir/ritonavir; DSV: Dasabuvir; VEL: Veltapasvir; GZR: Grazobuvir; EBR: Elbasvir; ASV: Asunaprevir; BCV: Beclabuvir; FDV: Faldaprevir.